[ad_1] Advisory Committee Voted 10 to 6 in Favor, Concluding that Elamipretide is Effective for the Treatment of Barth Syndrome Elamipretide NDA Received Priority Review with a PDUFA Action Date of January 29, 2025 If Approved, Elamipretide […]
Tag: Stealth BioTherapeutics Inc.
Stealth BioTherapeutics Announces FDA Advisory Committee Meeting to Review Elamipretide for Barth Syndrome Treatment
[ad_1] Meeting Scheduled with Cardiovascular and Renal Drugs Advisory Committee on October 10, 2024 NEEDHAM, Mass., Sept. 9, 2024 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery, […]
